{"schema_version":"1.0","type":"article","title":"BeOne Bets on Four RAS Drugs: The Real Asset Is Development Optionality","url":"https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs-en.md","lang":"en","date":"2026-08-22","publish_at":"2026-08-22T08:00:00+08:00","updated_at":"2026-08-22","category":"商業分析系列","topic":"商業分析系列","tags":["BeOne Medicines","Revolution Medicines","RAS(ON)","daraxonrasib","zoldonrasib","BGB-58067","BG-T187","biotech licensing","oncology","drug development"],"summary":"BeOne is taking regional rights to four RAS(ON) programs, opening two candidate combination routes and funding one global registrational Phase 3. The strategic asset is not the sum of four drugs, but the optionality to decide where capital and development speed matter most.","key_points":[],"facts":[],"sections":["01 | Four RAS strategies enter at different stages","02 | The combinations are the most ambitious part of the deal","03 | The Asian rights look broad, but the disclosed boundary is narrow","04 | The biggest unanswered question: which program gets the global Phase 3?","05 | What did each company actually buy?","References","Disclaimer"],"references":[{"title":"[Revolution Medicines: clinical development and regional commercialization collaboration announcement, August 10, 2026]","source":"","date":"","url":"https://revmed.gcs-web.com/news-releases/news-release-details/revolution-medicines-and-beone-medicines-announce-clinical"},{"title":"[BeOne Medicines: clinical development and regional commercialization collaboration announcement, August 10, 2026]","source":"","date":"","url":"https://ir.beonemedicines.com/news/BeOne-Medicines-and-Revolution-Medicines-Announce-Clinical-Development-and-Regional-Commercialization-Collaboration/0a35a8d0-de94-4e43-a54c-c08af0e2e7ad"},{"title":"[SEC: BeOne Medicines first-quarter 2026 Form 10-Q cover data]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1651308/000162828026030867/R1.htm"},{"title":"[BeOne Medicines: Hong Kong investor site in Traditional Chinese]","source":"","date":"","url":"https://hkexir.beonemedicines.com/zh-hant"},{"title":"[Revolution Medicines: clinical development pipeline]","source":"","date":"","url":"https://www.revmed.com/pipeline/"},{"title":"[Revolution Medicines: FDA accepts daraxonrasib NDA, July 22, 2026]","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-new-drug-application-daraxonrasib-accepted/"},{"title":"[Revolution Medicines: RASolute 305 global Phase 3 begins treating patients, June 23, 2026]","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-begins-treating-patients-rasolute-305-phase/"},{"title":"[ClinicalTrials.gov: elironrasib and daraxonrasib Phase 1b/2, NCT06128551]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06128551"},{"title":"[Revolution Medicines: first patient dosed with RMC-5127, January 29, 2026]","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-doses-first-patient-clinical-trial/"},{"title":"[ClinicalTrials.gov: RMC-5127 Phase 1/1b, NCT07349537]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07349537"},{"title":"[BeOne Medicines: oncology pipeline]","source":"","date":"","url":"https://beonemedicines.com/science/pipeline/"},{"title":"[BeOne Medicines: global clinical development pipeline]","source":"","date":"","url":"https://beonemedicines.com/wp-content/uploads/2026/02/Clinical-Pipeline_2026-February.pdf"},{"title":"[ClinicalTrials.gov: BGB-58067, NCT06589596]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06589596"},{"title":"[ClinicalTrials.gov: BG-T187, NCT06598800]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06598800"},{"title":"Verification cutoff: August 12, 2026.","source":"","date":"","url":""}],"images":[{"alt":"Figure 1 | The four RAS(ON) programs span multi-selective, G12D, G12C and G12V strategies, with maturity ranging from NDA review to early clinical development","url":"https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs-en/figure-01.png"},{"alt":"Figure 2 | BGB-58067 and BG-T187 may be paired with daraxonrasib or zoldonrasib, but fixed combinations, tumor types, doses and timing remain undisclosed","url":"https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs-en/figure-02.png"},{"alt":"Figure 3 | The collaboration covers four RAS(ON) programs, selected Asian markets and one global registrational Phase 3, while the country list, economics and Phase 3 program remain undisclosed","url":"https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs-en/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-22）。BeOne Bets on Four RAS Drugs: The Real Asset Is Development Optionality。https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-22-revolution-medicines-beone-four-ras-programs.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}